Ch
EN
Home
About Us
Company Profile
Management Team
Company Culture
Enterprise Honor
Investor Relations
News
Industry News
Policies and Regulations
Products
Product List
R&D
Technology
Professionals
Clinical Findings
Literature Downloads
FAQ
Patients
Join us
TEAM
Contact Us
Home
>
News
>
Policies and Regulations
News
Industry News
Policies and Regulations
Policies and Regulations
2016 Annual Report for National Adverse Drug Reaction Monitoring released
发布时间:2017-05-02
On April 28, 2017, China Food and Drug Administration released the 2016 Annual Report for National Adverse Drug Reaction Monitoring. The Annual Report consists of four parts, namely: the progress of China's adverse drug reaction (ADR) monitoring in 2016, the situation of ADR reporting, the risk control measures, and five focused on aspects.
In 2016, China's national ADR monitoring continuously and effectively carried out; the number of ADR case reports further increased; the ability of analysis and evaluation gradually improved; and the capability of warning and disposal continuously strengthened. National ADR monitoring played an important role in ensuring drug safety for the public and advancing drug safety supervision.
(Source: CFDA)
上一篇:
CFDA releases 2016 Annual Report for National Medical Device Adverse Event Monitoring
下一篇:
CFDA issues Provisions for Medical Device Standards